Simcha Therapeutics

A small lab with a very specific grudge

Right now, inside a research building in New Haven, a protein is being grown that does not exist in nature. It looks almost exactly like interleukin-18, one of the immune system's oldest alarm signals. Almost. The difference is a handful of mutations, and those mutations are the entire point. This version will not answer when cancer calls. That protein is ST-067, and the company that built it is Simcha Therapeutics.

Simcha is not a household name. It has roughly twelve employees, one headquarters, and a pipeline you could explain on a napkin. What it has instead of size is a thesis - a single, sharp idea about why decades of cytokine cancer drugs kept failing, and what to do about it.

Cytokines were the great disappointment of cancer medicine

Cytokines are the messages immune cells send each other. In theory, dose a patient with the right one and you wake the immune system up to attack a tumor. In practice, this has been one of oncology's most reliable heartbreaks. The doses needed to do anything useful were often toxic, and the body had elegant ways of muffling the signal before it landed.

IL-18 was a particularly cruel tease. It is a potent activator of T cells and natural killer cells - exactly the cells you want hunting a tumor. But evolution gave IL-18 a built-in volume knob: a separate protein called IL-18 binding protein, or IL-18BP, that floats through the body soaking up free IL-18 like a sponge. Tumors, being opportunists, learned to flood their surroundings with extra IL-18BP. The alarm rings; nobody hears it.

A Yale immunologist, a test tube, and directed evolution

The bet was placed by Aaron Ring, then an Assistant Professor of Immunobiology at Yale School of Medicine. Rather than design a better IL-18 by hand - a task roughly as humble as redrafting a protein evolution spent millions of years tuning - Ring let evolution do the work, just faster. Using directed evolution, his lab generated enormous libraries of IL-18 variants and selected, round after round, for the ones that kept their punch but shrugged off IL-18BP.

The result was a "decoy-resistant" IL-18: a molecule that retains full immune-activating power yet is, in the company's words, completely impervious to the decoy protein. In animal models it produced potent antitumor effects on its own and worked even better alongside anti-PD-1 checkpoint inhibitors. The work was striking enough to land in Nature in June 2020.

A paper is not a company. So in 2018, around the science, Simcha Therapeutics was incorporated, with Ring as founder and the Yale work as its seed. The wager was simple and unfashionable: that one mechanistic insight, executed carefully, was worth more than a sprawling pipeline of maybes.

ST-067, and the art of ignoring a decoy

ST-067 is Simcha's lead program and the clearest expression of the thesis. It is IL-18, re-engineered to be deaf to IL-18BP. Drop it into the tumor microenvironment - the hostile little neighborhood a cancer builds around itself - and the immune-activating signal stays loud, because the decoy can no longer catch it.

The company is now running ST-067 through a Phase 1a/2 clinical trial in patients with diverse solid tumors who have already progressed on existing immunotherapies - the hardest cases, the ones where the easy answers have run out. One cohort pairs ST-067 with pembrolizumab, the checkpoint inhibitor better known as Keytruda, on the theory that an awakened immune system and an unblocked one are better together than apart.

Money, partners, and a stack of receipts

Skepticism is the correct default for any biotech with a single lead drug and a tidy origin story. So here are the receipts. In January 2022, Simcha raised a $40 million Series B led by SR One Capital Management, with BVF Partners, Samsara BioCapital, Rock Springs Capital, ArrowMark Partners and Logos Capital joining in. That round pushed total funding to roughly $69 million - real capital, from investors who do this for a living.

The bigger endorsement is harder to buy. In January 2024, Janssen Biotech - a Johnson & Johnson company - signed a license and option agreement to use Simcha's decoy-resistant IL-18 to armor select CAR T-based cell therapies. When one of the largest pharmaceutical companies on earth wants to bolt your molecule onto its cell therapies, it is making a statement about whose science it trusts.

And the work keeps widening. By October 2025, Simcha was presenting preclinical data showing its decoy-resistant IL-18 could enhance bispecific T-cell engagers - evidence that the one idea is less a single drug than a component other immune therapies might be built to carry.

Harnessing the immunobiology nobody else used

Simcha describes its work as creating innovative therapies that harness untapped immunobiology. The phrase is doing more work than it looks. "Untapped" is the whole pitch: the company is not inventing new biology so much as finishing the job evolution started and tumors learned to sabotage. The ambition Ring stated plainly - to become a leader in the next generation of cytokine immunotherapies - is less about one drug than about rehabilitating a whole class of them.

It is a focused bet in an industry that rewards breadth. Most biotechs hedge with a dozen programs. Simcha picked one mechanism, engineered it well, and let the partnerships argue for the platform.

If the decoy stops working, a lot changes

Cancer immunotherapy spent the last decade obsessed with checkpoints - the brakes tumors press to stop immune cells. Checkpoint inhibitors were a genuine revolution, and also a partial one; for many solid tumors, releasing the brake is not enough if the engine was never running. Cytokines are the engine. If a decoy-resistant cytokine can reliably run that engine inside hostile tumor tissue, it changes what combinations doctors can reach for next.

That is the future the J&J deal and the bispecific data hint at: not a single drug fighting alone, but a decoy-proof signal that makes checkpoint inhibitors, CAR T cells, and T-cell engagers each work a little harder. The patients who matter most here are the ones who have already failed the existing options - the cohort in Simcha's own trial. For them, "a little harder" is not a small word.

Back in that New Haven lab, the protein that does not exist in nature is still being grown. It still looks almost exactly like IL-18. The difference is still the entire point. Cancer built a decoy and spent millions of years counting on it. Simcha Therapeutics built a cytokine that doesn't bother to look.